THERAPEUTIC DRUGS TREATMENT

Brand Owner (click to sort) Address Description
AIP ORGENESIS INC. 20271 Goldenrod Lane Germantown MD 20876 Therapeutic drugs for the treatment of Pancreatectomy;
AUTOLOGOUS INSULIN PRODUCING CELLS (AIP) ORGENESIS INC. 20271 Goldenrod Lane Germantown MD 20876 Therapeutic drugs for the treatment of Pancreatectomy;AUTOLOGOUS INSULIN PRODUCING CELLS;
MOTC ORGENESIS INC. 20271 Goldenrod Lane Germantown MD 20876 Therapeutic drugs for the treatment of cancer;
MYOGEN Myogen, Inc. 7577 West 103rd Avenue Suite 212 Westminster CO 800215426 Therapeutic drugs for the treatment of heart muscle disease;
ONCARLYTICS Priceman, Saul 12212 Otsego St Valley Village CA 91607 Therapeutic drugs for the treatment of cancer;
ORGCAR19 ORGENESIS INC. 20271 Goldenrod Lane Germantown MD 20876 Therapeutic drugs for the treatment of cancer;ORGCAR NINETEEN;
ORGCAR19/22 ORGENESIS INC. 20271 Goldenrod Lane Germantown MD 20876 Therapeutic drugs for the treatment of cancer;ORGCAR NINETEEN/TWENTY TWO;
RANIN ORGENESIS INC. 20271 Goldenrod Lane Germantown MD 20876 Therapeutic drugs for the treatment of human papilloma virus, human immunodeficiency virus, and a range of severe acute respiratory syndromes;RAN IN;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. In addition to reducing or substantially eliminating a biological organism's reaction to the introduction of the medical device to the organism, the medical device in combination with one or more therapeutic drugs, agents and/or compounds may be utilized to treat various vascular diseases, for example, restenosis and vulnerable plaque. In the case of vulnerable plaque, one or more drugs, agents or compounds may be utilized to treat the various aspects of vulnerable plaque and these drugs, agents and/or compounds may be released with a given release profile for the most effective treatment. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.